Aris Interna. (531677)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive trailing earnings implied by the P/E of 441.77, so it is not a loss-making shell.
• Reported ROE of 23.55% suggests the small equity base has generated strong past returns.
• Book value is positive at ₹3.87 per share, giving some residual net-asset cushion.

Concerns

• Extreme valuation: P/E of 441.77 and P/B of 15.60 despite zero sales and profit growth.
• Latest quarter shows ₹0 crore sales and ₹0 crore net profit, indicating business activity may have stalled.
• ROCE of only 5.16% and Piotroski F-Score of 4/9 point to weak operating returns and fragile financial health.
• No dividend and a price far below the stated 52-week range of ₹317.10–₹608.00 signal severe loss of investor confidence.

AI Analysis

Let me start with what I look for: a simple business, a durable moat, high returns on capital, and a price that gives me a margin of safety. Aris Interna fails most of those tests. At ₹60.37 the market cap is just ₹57 crore, but I am asked to pay 441.77 times earnings and 15.60 times book value when book value is only ₹3.87. That is not a value price; that is a hope-and-a-prayer price. The reported ROE of 23.55% sounds good, but ROCE is only 5.16%, so the operating business is not earning anywhere near what the equity return suggests. Sales growth and profit growth are both 0.00%, and the latest quarter shows ₹0 crore in sales and ₹0 crore in net profit. If there is no current revenue and no profit, there is no fundamental engine to justify a 441 P/E. The Piotroski F-Score of 4/9 is weak, the dividend yield is zero, and the 52-week range of ₹317.10 to ₹608.00 versus today's ₹60.37 tells me this stock has already broken most investors. In Graham's language, price is what you pay, value is what you get. Here the price is high in every meaningful ratio, while the value evidence is missing. I cannot take comfort from a PEG ratio of 2.95 because with zero growth, PEG is meaningless. This looks like a possible turnaround situation, not a proven compounder. I would need to see many quarters of real revenue, real profit, and a much lower price before I would part with my money. For now, I simply cannot understand how this is an investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer